Stereotaxis (STXS) Earns News Sentiment Rating of 0.44
News headlines about Stereotaxis (NASDAQ:STXS) have trended positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stereotaxis earned a media sentiment score of 0.44 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.0042706589155 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Stereotaxis (NASDAQ STXS) traded up 8.00% during mid-day trading on Friday, hitting $0.96. The stock had a trading volume of 50,264 shares. The company’s market cap is $21.70 million. Stereotaxis has a 12 month low of $0.47 and a 12 month high of $0.97. The firm’s 50-day moving average is $0.72 and its 200 day moving average is $0.62.
Stereotaxis (NASDAQ:STXS) last released its quarterly earnings data on Thursday, August 10th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $8.47 million during the quarter. Equities analysts anticipate that Stereotaxis will post ($2.03) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Stereotaxis (STXS) Earns News Sentiment Rating of 0.44” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/10/08/stereotaxis-stxs-earns-news-sentiment-rating-of-0-44.html.
Stereotaxis, Inc is a United States-based healthcare technology company. The Company is engaged in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease. The Company also provides information management solutions for the interventional lab.
Receive News & Stock Ratings for Stereotaxis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis Inc and related stocks with our FREE daily email newsletter.